ライフサイエンスコーパス: quetiapine

1 stent with the known tolerability profile of quetiapine.

2 one, and risperidone was more effective than quetiapine.

3 s for clozapine, olanzapine, risperidone, or quetiapine.

4 idone and typical neuroleptics, and low with quetiapine.

5 to clozapine, and only 14% were switched to quetiapine.

6 llowing Successful Treatment with Lithium or Quetiapine.

7 ent with lithium, valproate, olanzapine, and quetiapine.

8 likely in participants taking 300 mg/day of quetiapine.

9 n is variable with the clearest evidence for quetiapine.

10 Tests with quetiapine (0 vs. 7.5 mg/kg) in a within-subject design

11 nterval), olanzapine was more effective than quetiapine (-0.29; -0.56 to -0.02), haloperidol (-0.29;

12 speridone=28.0%, typical neuroleptics=14.5%, quetiapine=0.0%).

13 apine (risk ratio: 1.03, 95% CI, 0.78-1.32), quetiapine (1.02, 95% CI, 0.72-1.32), and risperidone (0

14 o treatment with olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day), or risperidone (0.5-4 mg/da

15 o treatment with olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day), or risperidone (0.5-4 mg/da

16 ol injection=62, olanzapine=144, placebo=75, quetiapine=125, risperidone=124, UC=30 and ziprasidone=3

17 ved olanzapine, 16% of patients who received quetiapine, 18% of patients who received risperidone, an

18 .02) with an NNH of 40 (95% CI, 21-312); and quetiapine, 2.0% (95% CI, 0.7%-3.3%; P < .01) with an NN

19 per day), perphenazine (8 to 32 mg per day), quetiapine (200 to 800 mg per day), or risperidone (1.5

20 psychotic (olanzapine, 7.5-30 mg/day [N=66]; quetiapine, 200-800 mg/day [N=63]; risperidone, 1.5-6.0

21 en groups, more somnolence was observed with quetiapine (22% vs. 11%; p = .66).

22 d to olanzapine, 26% of patients assigned to quetiapine, 29% of patients assigned to risperidone, and

23 onths) and olanzapine (6.3 months) than with quetiapine (4.0 months) and ziprasidone (2.8 months).

24 total of 1,953 patients received open-label quetiapine (400-800 mg/day in flexible, divided doses) w

25 pe 2 diabetes during treatment with low-dose quetiapine (425 cases) was 9.59 cases/1000 person-years

26 idone LAI, 120 mg every 4 weeks and 1.53 mg; quetiapine, 482 mg/day and 77 mg; risperidone, 6.3 mg/da

27 Patients were randomized to receive quetiapine 50 mg every 12 hrs or placebo.

28 ne (409; 95% CI, 345-483 per 10000 PYAR), or quetiapine (582; 95% CI, 489-692 per 10000 PYAR).

29 ridone extended-release, 9 or 12 mg/day, and quetiapine, 600 or 800 mg/day.

30 erphenazine, 82 percent of those assigned to quetiapine, 74 percent of those assigned to risperidone,

31 nd risperidone (26.7 weeks) as compared with quetiapine (9.1 weeks) and placebo (9.0 weeks) (P=0.002)

32 Quetiapine added to as-needed haloperidol results in fas

33 HR], 0.91, 95% CI, 0.82 to 1.01, p = 0.078), quetiapine (aHR, 0.94, 95% CI, 0.85 to 1.04, p = 0.230),

34 Of specific drugs, high-dose quetiapine (AHR, 1.78 [95% CI, 1.22-2.60]; P = .003), hi

35 ne (aHR=0.45, 95% CI: 0.28-0.71), sertraline-quetiapine (aHR=0.79, 95% CI: 0.67-0.93) and venlafaxine

36 aHR=0.79, 95% CI: 0.67-0.93) and venlafaxine-quetiapine (aHR=0.82, 95% CI: 0.73-0.91) vs. non-use of

37 -infinity to -3.9]; P < .001), but not with quetiapine alone vs placebo (42.8 vs 41.7 L/min; MD, 1.1

38 This dose of quetiapine also blocked the PPI-disruptive effects of ph

39 ], -0.03, 95% CI, -0.09 to 0.02, p = 0.261), quetiapine (aMD, -0.03, 95% CI, -0.09 to 0.03, p = 0.324

40 ole), abnormal metabolic laboratory results (quetiapine and OFC), and weight gain (all four drugs, es

41 2A) (5-HT(2A)) receptor antagonists, such as quetiapine and olanzapine, and mood-stabilizing voltage-

42 ntified between patients receiving high-dose quetiapine and placebo for both primary efficacy variabl

43 Short-term treatment with both quetiapine and risperidone resulted in improvements in s

44 han the atypical drugs, including clozapine, quetiapine and risperidone.

45 Exceptions were quetiapine and sertindole with negligible risks across a

46 de among antipsychotics, yet exceptions were quetiapine and sertindole with negligible risks.

47 done and olanzapine were more effective than quetiapine and ziprasidone as reflected by longer time u

48 (N=184), olanzapine was more effective than quetiapine and ziprasidone, and risperidone was more eff

49 rly lurasidone, olanzapine + fluoxetine, and quetiapine) and the anticonvulsant lamotrigine; value an

50 zophrenia were 0.19 for olanzapine, 0.34 for quetiapine, and 0.22 for risperidone.

51 e battery were 0.17 for olanzapine, 0.33 for quetiapine, and 0.32 for risperidone.

52 (SD=5.3) for olanzapine, 506 mg (SD=215) for quetiapine, and 2.4 mg (SD=1.0) for risperidone.

53 oses were 11.7 mg for olanzapine, 506 mg for quetiapine, and 2.4 mg for risperidone.

54 liperidone extended-release, 66.7% (106/159) quetiapine, and 63.8% (51/80) placebo.

55 brexpiprazole, cariprazine, extended-release quetiapine, and olanzapine-fluoxetine combination).

56 ively, in the paliperidone extended-release, quetiapine, and placebo groups.

57 e events with paliperidone extended-release, quetiapine, and placebo, respectively, were tremor (13.9

58 Olanzapine, quetiapine, and risperidone all produced significant imp

59 Olanzapine, quetiapine, and risperidone demonstrated comparable effe

60 However, only aripiprazole, olanzapine, quetiapine, and risperidone had better acceptability tha

61 = 56, n = 14503); aripiprazole, olanzapine, quetiapine, and risperidone had lower all-cause disconti

62 atment discontinuation rates) of olanzapine, quetiapine, and risperidone in patients early in the cou

63 t of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients wit

64 sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitive function i

65 generation agents, olanzapine, paliperidone, quetiapine, and risperidone were 61.5% (95% CI, 52.5-70.

66 n antipsychotics (eg, clozapine, olanzapine, quetiapine, and risperidone) are associated with an incr

67 up, the atypical antipsychotics (olanzapine, quetiapine, and risperidone) showed a dose-response incr

68 eration antipsychotic use (i.e., olanzapine, quetiapine, and risperidone) throughout the 36-week tria

69 r an antipsychotic (haloperidol, olanzapine, quetiapine, and risperidone), valproic acid and its deri

70 were 68.4%, 70.9%, and 71.4% for olanzapine, quetiapine, and risperidone, respectively.

71 ion compared to those prescribed olanzapine, quetiapine, and risperidone.

72 ute change in mortality risk for olanzapine, quetiapine, and risperidone.

73 le, olanzapine/fluoxetine combination (OFC), quetiapine, and risperidone.

74 Asenapine, lithium, olanzapine, quetiapine, and valproate outperformed placebo for all-c

75 udies comprising 66 risperidone, olanzapine, quetiapine, and ziprasidone arms including 7264 patients

76 (i.e., aripiprazole, lurasidone, olanzapine, quetiapine, and ziprasidone) with lithium or valproate (

77 showed superior efficacy versus haloperidol, quetiapine, and ziprasidone.

78 ine; 10,970 [48.4%], olanzapine; 955 [4.2%], quetiapine; and 9,903 [43.7%], risperidone; 387 patients

79 Antipsychotics, such as quetiapine, are frequently prescribed to people with dem

80 Antipsychotic agents, such as quetiapine, aripiprazole, asenapine, lurasidone, and car

81 e, and atypical antipsychotic drugs, such as quetiapine, aripiprazole, asenapine, lurasidone, and car

82 , that is, adding a second treatment (adding quetiapine, aripiprazole, buspirone alpha2delta ligand a

83 ychotic medication (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, asenapine, iloper

84 ssion for coronary disease, pain (small ES); quetiapine/aripiprazole/olanzapine induced WG (small to

85 These findings suggest quetiapine as a single agent is effective in treating mi

86 rescribed lithium, valproate, olanzapine, or quetiapine as maintenance mood stabilizer treatment.

87 7 prescribed olanzapine, and 1376 prescribed quetiapine as maintenance mood stabilizer treatment.

88 Initiation of quetiapine as treatment for severe anxiety that was unre

89 S) between paliperidone extended-release and quetiapine at the 2-week monotherapy phase endpoint.

90 asal spray as compared with extended-release quetiapine augmentation therapy, both in combination wit

91 shares these properties with olanzapine and quetiapine, but its affinity for muscarinic receptors ma

92 ents who received clozapine, olanzapine, and quetiapine, but not risperidone.

93 napine increased fasting glucose (small ES); quetiapine/cariprazine/risperidone induced WG (small/mod

94 onse to hypercapnia on days 1 and 5, whereas quetiapine combined with oxycodone did not cause such an

95 (n = 13), and underwent four-week rTMS with quetiapine concomitantly.

96 Quetiapine demonstrated the lowest placental passage of

97 paliperidone extended-release compared with quetiapine despite similar use of additive therapy (pred

98 lculated for the association with cumulative quetiapine dose.

99 a 1:1 ratio to receive treatment with either quetiapine (dose range: 200-800 mg/day) or risperidone (

100 When compared directly with quetiapine, dose-adjusted mortality risk was increased w

101 , weight gain (51%), and insomnia (38%); for quetiapine, drowsiness (58%), increased sleep hours (42%

102 ] of 57 patients; estimated 63.5%) than with quetiapine-ER (15 [30%] of 50; estimated 31.3%; p=0.0021

103 tly higher for aripiprazole (97.1%) than for quetiapine-ER (89.2%; p=0.012).

104 ility, of whom 113 were randomly assigned to quetiapine-ER (n=55) or aripiprazole (n=58).

105 Weight gain was more rapid with quetiapine-ER (p=0.0008), with an adjusted mean weight g

106 treatment with target doses of 600 mg/day of quetiapine-ER (starting from 50 mg/day) or 20 mg/day of

107 events were tremor (42 [79%] patients in the quetiapine-ER group vs 52 [91%] patients in the aripipra

108 ved at weeks 2, 4, and 12, respectively, for quetiapine-ER in 43 [83%] of 52, 40 [83%] of 48, and 34

109 ATION: This first head-to-head comparison of quetiapine-ER versus aripiprazole in early-onset psychos

110 Quetiapine-ER was associated with more metabolic adverse

111 y and safety of quetiapine-extended release (quetiapine-ER) versus aripiprazole in children and adole

112 weeks (adjusted mean change -5.05 [5.46] for quetiapine-ER, -6.21 [5.42] for aripiprazole; p=0.98), b

113 aimed to compare the efficacy and safety of quetiapine-extended release (quetiapine-ER) versus aripi

114 s, we suggest that use of off-label low-dose quetiapine for sedative or hypnotic purposes should be d

115 with paliperidone extended-release than with quetiapine from day 5 (-11.4 versus -8.2) through the mo

116 fumarate (< or = 750 mg/d), n = 96; low-dose quetiapine fumarate (< or = 250 mg/d), n = 94; or placeb

117 mized to 6 weeks of treatment with high-dose quetiapine fumarate (< or = 750 mg/d), n = 96; low-dose

118 , risperidone (1994), olanzapine (1996), and quetiapine fumarate (1997)-offer a decrease in serious a

119 Quetiapine fumarate (Seroquel [ICI 204,636]) is an atypi

120 , 1.58; 95% CI, 1.21-2.07; P = .001) but not quetiapine fumarate or olanzapine.

121 es, insulin, and insulin resistance, whereas quetiapine fumarate was associated with significantly hi

122 antipsychotics (risperidone, olanzapine, and quetiapine fumarate).

123 ifferences were also observed for clozapine, quetiapine fumarate, amitriptyline hydrochloride, mirtaz

124 ive treatment with olanzapine, perphenazine, quetiapine fumarate, or risperidone for up to 18 months

125 domly assigned to treatment with olanzapine, quetiapine fumarate, risperidone, or placebo with the op

126 isperidone, and 2.16 (95% CI, 1.88-2.48) for quetiapine fumarate.

127 ose value > or =126 mg/dl were higher in the quetiapine group (12.6% versus 5.4%; 18.44 versus 9.56 p

128 ratio=2.54, p=0.007) and the moderate-dosage quetiapine group (hazard ratio=2.37, p=0.011) than for t

129 ignificantly shorter for both the low-dosage quetiapine group (hazard ratio=2.54, p=0.007) and the mo

130 Fewer patients in the quetiapine group experienced a mood event compared with

131 patients in the esketamine group than in the quetiapine group had remission at week 8 (91 of 336 pati

132 Participants in the low-dosage quetiapine group had significant improvement on the Zana

133 al scores were significantly greater for the quetiapine group than for the placebo group.

134 o completed the study, 82% in the low-dosage quetiapine group were rated as "responders," compared wi

135 amine group) or extended-release quetiapine (quetiapine group), both in combination with an SSRI or S

136 atment phase was 67% (67% for the low-dosage quetiapine group, 58% for the moderate-dosage quetiapine

137 uetiapine group, 58% for the moderate-dosage quetiapine group, and 79% for the placebo group).

138 pothyroidism occurred more frequently in the quetiapine group, as did discontinuations due to adverse

139 igned to the esketamine group and 340 to the quetiapine group.

140 y clozapine (at dosages >=180 mg/d) but also quetiapine (>=440 mg/d) and olanzapine (>=11 mg/d).

141 Participants treated with 150 mg/day of quetiapine had a significant reduction in the severity o

142 ium, those taking valproate, olanzapine, and quetiapine had reduced rates of chronic kidney disease s

143 Quetiapine has been associated with increased risk of ty

144 used for schizophrenia or bipolar disorder, quetiapine has been associated with weight gain and incr

145 al ziprasidone (hazard ratio=1.13), and oral quetiapine (hazard ratio=1.11) were significantly associ

146 (hazard ratio=1.15); the diabetes risks for quetiapine (hazard ratio=1.20) and risperidone (hazard r

147 zapine HR 0.32; 95% CI 0.14-0.76; p = 0.008, quetiapine HR 0.23; 95% CI 0.07-0.73; p = 0.013) were al

148 zapine HR 0.57; 95% CI 0.45-0.71; p < 0.001, quetiapine HR 0.62; 95% CI 0.47-0.80; p < 0.001).

149 zapine HR 1.84; 95% CI 1.47-2.30; p < 0.001, quetiapine HR 1.67; 95% CI 1.24-2.20; p < 0.001) than in

150 peridone (HR = 1.60, 95% CI: 1.19, 2.14), or quetiapine (HR = 1.67, 95% CI: 1.01, 2.76).

151 l flupentixol (HR, 0.92; 95% CI, 0.74-1.14), quetiapine (HR, 0.91; 95% CI, 0.83-1.00), and oral perph

152 valproate (HR, 1.32; 95% CI, 1.10-1.58) and quetiapine (HR, 1.34; 95% CI, 1.07-1.69) but not olanzap

153 low and moderate dosages of extended-release quetiapine in adults with borderline personality disorde

154 primary care physician (PCP) prescribers of quetiapine in original Medicare.

155 th weight gain in women, with olanzapine and quetiapine in particular, and with unfavorable change in

156 buted to use of olanzapine, risperidone, and quetiapine in patients taking these medications.

157 s compared paliperidone extended-release and quetiapine in patients with recently exacerbated schizop

158 Greater improvements were also observed for quetiapine in scores on the Davidson Trauma Scale, CGI s

159 mild and expected based on prior studies of quetiapine in this and other patient population.

160 I deficits after BLA lesions are reversed by quetiapine, in a manner that is sustained beyond its acu

161 Quetiapine-initiators were matched 1:1 with initiators o

162 Quetiapine is an atypical antipsychotic agent with a com

163 Quetiapine is an effective antipsychotic with a favorabl

164 So, we conclude that the use of low-dose quetiapine is associated with an increased risk of major

165 Lurasidone+LIT/VAL and quetiapine+LIT/VAL outperformed placebo+LIT/VAL for all-

166 Lurasidone+LIT/VAL and quetiapine+LIT/VAL outperformed placebo+LIT/VAL for RR-d

167 Aripiprazole+LIT/VAL and quetiapine+LIT/VAL outperformed placebo+LIT/VAL for RR-m

168 Quetiapine (MD -3.60 95% CrI -4.83 to -2.39) had the lar

169 eive olanzapine (mean dose, 5.5 mg per day), quetiapine (mean dose, 56.5 mg per day), risperidone (me

170 3%), risperidone (mean=49.2%, SD=33.9%), and quetiapine (mean=23.8%, SD=11.0%).

171 any reason: olanzapine (median, 8.1 weeks), quetiapine (median, 5.3 weeks), risperidone (median, 7.4

172 for clozapine (median=10.5 months) than for quetiapine (median=3.3), or risperidone (median=2.8), bu

173 combined with quetiapine was not superior to quetiapine monotherapy in improving depressive symptoms

174 o-controlled trial to assess the efficacy of quetiapine monotherapy in the treatment of posttraumatic

175 nt in depressive symptoms over 12 weeks than quetiapine monotherapy plus lamotrigine placebo.

176 Quetiapine monotherapy was efficacious in the treatment

177 proate (n = 1670), olanzapine (n = 1477), or quetiapine (n = 1376) as maintenance mood stabilizer tre

178 th registers for data regarding new users of quetiapine (n = 185 938) or selective serotonin reuptake

179 45), by 6.1 kg (95% CI, 4.9 to 7.2 kg) with quetiapine (n = 36), by 5.3 kg (95% CI, 4.8 to 5.9 kg) w

180 signed to treatment with olanzapine (N=133), quetiapine (N=134), or risperidone (N=133).

181 , risperidone (N=80), olanzapine (N=63), and quetiapine (N=28) over a 3-month period were identified

182 olanzapine (N=319), risperidone (N=271), or quetiapine (N=94), the authors examined the impact of be

183 ly received in the trial (olanzapine [N=19], quetiapine [N=15], or risperidone [N=16]).

184 , olanzapine [N=31], risperidone [N=22], and quetiapine [N=9]).

185 idone (odds ratio: 1.53, 95% CI: 1.43-1.64), quetiapine (odds ratio: 1.52, 95% CI: 1.40-1.65), olanza

186 ncluding akathisia (aripiprazole), sedation (quetiapine, OFC, and aripiprazole), abnormal metabolic l

187 sed in the treatment of affective disorders (quetiapine, olanzapine, and semisodium valproate) during

188 Lithium, quetiapine, olanzapine, bupropion, and carbamazepine wer

189 ol, clozapine, aripiprazole, chlorpromazine, quetiapine, olanzapine, risperidone, and ziprasidone all

190 antipsychotic drugs (APDs), e.g., clozapine, quetiapine, olanzapine, risperidone, and ziprasidone, ha

191 Lithium, venlafaxine, bupropion, quetiapine, olanzapine, ziprasidone, valproic acid, carb

192 Future studies should evaluate the effect of quetiapine on mortality, resource utilization, post-inte

193 d the effects of (short-term) treatment with quetiapine on the risky decision-making of healthy human

194 omly assigned to double-blind treatment with quetiapine or placebo, in combination with lithium or di

195 e randomly assigned to treatment with either quetiapine or placebo.

196 with clozapine than in patients treated with quetiapine or risperidone but not olanzapine.

197 bacco users) with schizophrenia treated with quetiapine or risperidone monotherapy were randomized to

198 ymptom improvement, in patients treated with quetiapine or ziprasidone.

199 NNT, 7), OFC (OR, 1.30, 95% CI, 0.87-1.93), quetiapine (OR, 1.53, 95% CI, 1.17-2.0; NNT, 10), and ri

200 .48-2.73), OFC (OR, 1.42; 95% CI, 1.01-2.0), quetiapine (OR, 1.79; 95% CI, 1.33-2.42), and risperidon

201 scription of low-potency antipsychotics (eg, quetiapine) or off-label use of sedative antihistamines

202 APDs: olanzapine, risperidone, aripiprazole, quetiapine, or amisulpride.

203 Comedications containing corticosteroids, quetiapine, or antithrombotic agents were associated wit

204 Comedications containing corticosteroids, quetiapine, or antithrombotic agents were associated wit

205 ho initiated use of olanzapine, risperidone, quetiapine, or haloperidol in 1999-2001 after at least 3

206 h an antipsychotic (risperidone, olanzapine, quetiapine, or haloperidol) or valproic acid and its der

207 reatment with paliperidone extended-release, quetiapine, or placebo.

208 Treatment with aripiprazole, olanzapine, quetiapine, or risperidone for 12 weeks.

209 g the strategy of switching from olanzapine, quetiapine, or risperidone to aripiprazole to ameliorate

210 on a stable treatment dosage of olanzapine, quetiapine, or risperidone were randomly assigned to swi

211 sychotic monotherapy rather than olanzapine, quetiapine, or risperidone, might prevent/delay major ad

212 ly longer for clozapine than for olanzapine, quetiapine, or risperidone.

213 There is no association with olanzapine, quetiapine, or risperidone.

214 in children taking olanzapine, risperidone, quetiapine, or valproate.

215 LAI 1-monthly, asenapine-OS, haloperidol-OS, quetiapine-OS, cariprazine-OS, and lurasidone-OS.

216 otrigine+valproate, lithium, olanzapine, and quetiapine outperformed placebo for RR-dep.

217 2), 0.25 for perphenazine (P<.001), 0.18 for quetiapine (P<.001), 0.26 for risperidone (P<.001), and

218 y longer in the olanzapine group than in the quetiapine (P<0.001) or risperidone (P=0.002) group, but

219 Compared with quetiapine, paliperidone extended-release improved sympt

220 SRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remissio

221 med to determine if combination therapy with quetiapine plus lamotrigine leads to greater improvement

222 authors evaluated the efficacy and safety of quetiapine plus lithium or divalproex in the prevention

223 In patients stabilized on quetiapine plus lithium or divalproex, continued treatme

224 01) but was not significantly decreased with quetiapine plus oxycodone vs placebo plus oxycodone on d

225 The combination of lamotrigine plus quetiapine potentially offers improved outcomes for peop

226 Quetiapine prescriptions were limited to tablet strength

227 d to be >/= 15.5 mug/capita/day, followed by quetiapine (QTP; 8.51 mug/capita/day), citalopram (CLP;

228 spray (esketamine group) or extended-release quetiapine (quetiapine group), both in combination with

229 (relative risk=0.91, 95% CI=0.78-1.06), and quetiapine (relative risk=0.73, 95% CI=0.67-0.80).

230 Subjects treated with quetiapine required fewer days of as-needed haloperidol

231 With olanzapine and quetiapine, respectively, mean levels increased signific

232 d exposures of doxazosin, tamsulosin, and/or quetiapine, resulting in additional alpha-adrenergic blo

233 lithium+valproate, olanzapine, paliperidone, quetiapine, risperidone long-acting injection, valproate

234 racetam, amantadine, selegiline, olanzapine, quetiapine, risperidone, and citalopram do not appear to

235 mmonly used drugs (aripiprazole, olanzapine, quetiapine, risperidone, and haloperidol).

236 o atypical antipsychotic drugs, specifically quetiapine, risperidone, and olanzapine, are known to ca

237 zed, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who

238 Quetiapine, risperidone, and ziprasidone use were not as

239 napine, iloperidone, lurasidone, olanzapine, quetiapine, risperidone, and ziprasidone.

240 ent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.

241 and atypical APMs (aripiprazole, olanzapine, quetiapine, risperidone, etc).

242 ed, flexible-dose treatment with olanzapine, quetiapine, risperidone, or placebo for up to 36 weeks.

243 to receive masked, flexible-dose olanzapine, quetiapine, risperidone, or placebo.

244 ssigned to receive olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone for up to 18 mon

245 who discontinued treatment with olanzapine, quetiapine, risperidone, or ziprasidone in phase 1 or 1B

246 zole, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, risperidone long-acting injecti

247 operidol, lithium, olanzapine, paliperidone, quetiapine, risperidone, tamoxifen, valproate, and zipra

248 operidol, lithium, olanzapine, paliperidone, quetiapine, risperidone, tamoxifen, valproate, and zipra

249 operidol, lithium, olanzapine, paliperidone, quetiapine, risperidone, valproate, and ziprasidone had

250 BPRS positive-symptom cluster score showing quetiapine's consistency in reducing positive symptoms.

251 e and risperidone showed declining rates and quetiapine showed an increase during the early-warning p

252 de was superior for reduction of symptoms to quetiapine (SMD -0.25, 95% CI -0.50 to -0.01).

253 , haloperidol (SMD=0.27, 95% CI: 0.14-0.39), quetiapine (SMD=0.25, 95% CI: 0.12-0.38), aripiprazole (

254 eatment with lithium was superior to that of quetiapine, suggesting the importance of having lithium

255 ar connectome normalization with lithium and quetiapine suggests that the connectome changes are a do

256 reatment scores improved more rapidly in the quetiapine than lithium treated group, as did significan

257 pid functional brain changes associated with quetiapine than lithium treatment in youth with bipolar

258 e randomly assigned to receive 150 mg/day of quetiapine (the low-dosage group; N=33), 300 mg/day of q

259 (the low-dosage group; N=33), 300 mg/day of quetiapine (the moderate-dosage group; N=33), or placebo

260 s than 1 year of olanzapine, risperidone, or quetiapine therapy.

261 Addition of lamotrigine to quetiapine treatment improved outcomes.

262 Quetiapine treatment was associated with a marked tenden

263 Olanzapine and quetiapine treatments were significantly associated with

264 ed order for 5 days: paroxetine 40 mg daily, quetiapine twice daily (increasing daily doses from 100

265 , N=1,235), olanzapine (two studies, N=610), quetiapine (two studies, N=386), amisulpride (one study,

266 The intervention reduced quetiapine use among both nursing home patients (adjuste

267 Compared to SSRIs, low-dose quetiapine use was associated with an increased risk of

268 In as-treated analysis, continuous low-dose quetiapine use was associated with increased risk of maj

269 Altogether, we compared 60,566 low-dose quetiapine users with 454,567 Z-drug users, followed for

270 , using a case-control approach nested among quetiapine users.

271 < .01) with an NNH of 31 (95% CI, 21-62) for quetiapine users.

272 CI, 1.12-1.74 for valproate, olanzapine, or quetiapine vs lithium) and PS matching (HR, 1.51; 95% CI

273 ) and intensive care unit length of stay (16 quetiapine vs. 16 days) were similar, subjects treated w

274 Whereas mortality (11% quetiapine vs. 17%) and intensive care unit length of st

275 be discharged home or to rehabilitation (89% quetiapine vs. 56%; p =.06).

276 r, a pooled analysis of 3 trials showed that quetiapine was associated with a 26% greater likelihood

277 spitalization compared with oral olanzapine; quetiapine was associated with a 36% worse outcome in te

278 Quetiapine was associated with a shorter time to first r

279 In intention-to-treat analysis, low-dose quetiapine was associated with an increased risk of majo

280 Quetiapine was associated with benefits in the treatment

281 Quetiapine was associated with the highest risk of relap

282 Of 280 patients in whom the efficacy of quetiapine was evaluated, 159 (42% of those receiving hi

283 ng letters stating that their prescribing of quetiapine was high and under review by Medicare.

284 Quetiapine was increased every 24 hrs (50 to 100 to 150

285 In this cohort study, use of low-dose quetiapine was not associated with excess risk of type 2

286 findings indicated active rTMS combined with quetiapine was not superior to quetiapine monotherapy in

287 Once a therapeutic dose of quetiapine was reached, ventilator support was removed w

288 After a 1-week placebo run-in, quetiapine was started at a daily dosage of 25 mg and in

289 tive symptoms was less consistent; high-dose quetiapine was superior on the Modified Scale for the As

290 Quetiapine was the least prescribed of the newer drugs.

291 The atypical antipsychotic quetiapine was used to reverse PPI deficits after basola

292 Quetiapine was well tolerated and did not induce extrapy

293 5% weight gain on valproate, olanzapine, and quetiapine were higher (valproate HR 1.62; 95% CI 1.31-2

294 16 days) were similar, subjects treated with quetiapine were more likely to be discharged home or to

295 and patients who had stable prescriptions of quetiapine were the most likely to be switched (37%).

296 as prescribed more often than risperidone or quetiapine, which were prescribed more often than other

297 und no dose-response association of low-dose quetiapine with diabetes (OR for doubling of the cumulat

298 of drugs to treat parkinsonian symptoms and quetiapine with less akathisia than haloperidol, aripipr

299 Twenty participants received 150 mg of quetiapine XL for 7 d, whereas 20 age- and IQ-matched pa

300 ., aripiprazole, brexpiprazole, cariprazine, quetiapine XR) are proven effective as adjunctive treatm